Drug Pricing Transparency: Study Mandated on Supply Chain Compensation.
This Act mandates the Government Accountability Office (GAO) to conduct a detailed study on how intermediaries in the prescription drug supply chain (like pharmacy benefit managers and wholesalers) structure their fees and compensation based on the drug's price. The goal is to uncover whether current payment mechanisms lead to higher costs for patients or create conflicts of interest. The findings will provide Congress with recommendations for future legislative action to potentially lower drug costs.
Key points
The government will conduct a two-year study to understand how intermediary fees and compensation are tied to the price of prescription drugs.
The study aims to identify potential conflicts of interest that might favor the selection of higher-priced medications.
The resulting report will provide Congress with recommendations that could lead to future legislation aimed at reducing drug costs for citizens.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.